European Parliament
Philippe Boulland  (PPE ),
in writing.
(FR)
In the EU, counterfeit goods cost European businesses EUR 250 billion each year. This report extends the scope of customs enforcement to a greater range of intellectual property rights. With regard to the checking of in-transit medicines by customs, this will only be carried out where there are sufficient grounds to suspect that the medicines are intended for sale in the Union. Therefore, this report in no way prevents medicines from being marketed, but encourages vigilance where counterfeiting is concerned.

